Deadman J J, Elgendy S, Goodwin C A, Green D, Baban J A, Patel G, Skordalakes E, Chino N, Claeson G, Kakkar V V
Thrombosis Research Institute, London, United Kingdom.
J Med Chem. 1995 Apr 28;38(9):1511-22. doi: 10.1021/jm00009a012.
Z-D-Phe-Pro-boroMpg-OPin (9a)1,2 has been shown previously to be a highly specific inhibitor of thrombin in spite of lacking an arginine-like guanidino group at the P1 site. A range of compounds have been synthesized based upon this lead compound, varying the neutral side chain at the P1 site. Of the 20 examples based upon the structures at P2 and P3 of Z-D-X-Pro (X being Phe or beta,beta-diphenylalanine), all were found to be effective inhibitors of thrombin (Ki's between 10 and 100 nM). Furthermore all exhibited a high specificity toward thrombin having values for a Ki(trypsin)/Ki(thrombin) ratio of between 10- and 100-fold. High ratio values were found for a number of the compounds tested against a range of serine proteinases (plasmin, factor Xa, kallikrein, urokinase, protein Ca, chymotrypsin, elastase, and cathepsin G). As far as potency toward thrombin, compounds containing the methoxypropyl group at P1 were favored over those with a methoxy grouping on a shorter alkyl chain (8) or without the methoxy group (1-5). The compounds display potent anticoagulant activity with values for 18 in thrombin time of 0.63 microM and in activated partial thromboplastin time of 2.0 microM. 11B NMR has been used to confirm interaction of the boron atom with the active site. From the high specificity shown with all the compounds we propose that the compounds, constitute a new class of thrombin inhibitors.
Z-D-苯丙氨酸-脯氨酸-硼甲基苯丙氨酸-OPin(9a)1,2先前已被证明是一种高度特异性的凝血酶抑制剂,尽管其P1位点缺乏类似精氨酸的胍基。基于该先导化合物合成了一系列化合物,改变了P1位点的中性侧链。在基于Z-D-X-脯氨酸(X为苯丙氨酸或β,β-二苯基丙氨酸)的P2和P3结构的20个实例中,所有化合物均被发现是有效的凝血酶抑制剂(Ki值在10至100 nM之间)。此外,所有化合物对凝血酶均表现出高特异性,Ki(胰蛋白酶)/Ki(凝血酶)比值在10至100倍之间。在针对一系列丝氨酸蛋白酶(纤溶酶、因子Xa、激肽释放酶、尿激酶、蛋白C、胰凝乳蛋白酶、弹性蛋白酶和组织蛋白酶G)测试的许多化合物中发现了高比值。就对凝血酶的效力而言,P1位点含有甲氧基丙基的化合物优于那些在较短烷基链上带有甲氧基的化合物(8)或没有甲氧基的化合物(1-5)。这些化合物显示出强大的抗凝活性,凝血酶时间为0.63 microM,活化部分凝血活酶时间为2.0 microM。11B NMR已用于确认硼原子与活性位点的相互作用。从所有化合物显示的高特异性来看,我们提出这些化合物构成了一类新的凝血酶抑制剂。